Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Opening Session Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Dec
24
Today In Oncology
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo